Antiphosphatidylserine Antibodies and Clinical Outcomes in Patients With Acute Ischemic Stroke | Zendy

Xiaoqing Bu | Zendy; Hao Peng | Zendy; Chongke Zhong | Zendy; Tan Xu | Zendy; Tian Xu | Zendy; Yanbo Peng | Zendy; Chung-Shiuan Chen | Zendy; Jinchao Wang | Zendy; Zhong Ju | Zendy; Qunwei Li | Zendy; Deqin Geng | Zendy; Yingxian Sun | Zendy; Dongsheng Zhang | Zendy; Jintao Zhang | Zendy; Jing Chen | Zendy; Yonghong Zhang | Zendy; Jiang He | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiphosphatidylserine Antibodies and Clinical Outcomes in Patients With Acute Ischemic Stroke

Author(s) -

Xiaoqing Bu,

Hao Peng,

Chongke Zhong,

Tan Xu,

Tian Xu,

Yanbo Peng,

Chung-Shiuan Chen,

Jinchao Wang,

Zhong Ju,

Qunwei Li,

Deqin Geng,

Yingxian Sun,

Dongsheng Zhang,

Jintao Zhang,

Jing Chen,

Yonghong Zhang,

Jiang He

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.013827

Subject(s) - medicine , stroke (engine) , ischemic stroke , acute stroke , antibody , cardiology , intensive care medicine , emergency medicine , ischemia , immunology , tissue plasminogen activator , mechanical engineering , engineering

Antiphosphatidylserine antibodies (aPS) have been associated with the risk of ischemic stroke. However, it remains unclear whether aPS will influence clinical outcomes in patients with acute ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research